Current Report Filing (8-k)
April 01 2021 - 08:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): March 31,
2021
AzurRx BioPharma, Inc.
(Exact Name of Registrant as Specified in
Charter)
|
|
|
|
|
Delaware
|
|
001-37853
|
|
46-4993860
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
1615 South Congress Avenue, Suite 103
Delray Beach, Florida 33445
(Address of Principal Executive Offices, and Zip Code)
(646) 699-7855
Registrant’s Telephone Number, Including Area
Code
Not Applicable
(Former Name or Former Address, if Changed Since Last
Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
[
] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[
] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
[
] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[
] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the
Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common
Stock, par value $0.0001 per share
|
AZRX
|
Nasdaq
Capital Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17
CFR §230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2 of this
chapter).
Emerging growth company [X]
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 7.01 Regulation FD Disclosure
On
March 31, 2021, AzurRx BioPharma, Inc. (the “Company”)
issued a press release summarizing certain matters discussed on an
investor call reporting topline results from its Phase 2b OPTION 2
clinical trial investigating MS1819 in cystic fibrosis patients
with exocrine pancreatic insufficiency. A copy of the press release
is furnished as Exhibit 99.1 to this Form
8-K.
Item 9.01. Financial Statements and Exhibits.
Exhibit
No.
|
Description
|
|
Press
Release dated March 31, 2021
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
April
1, 2021
|
AzurRx BioPharma, Inc.
By:
/s/
James Sapirstein
Name:
James Sapirstein
Title:
President, Chief Executive Officer and Chairman
|
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From Feb 2024 to Mar 2024
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From Mar 2023 to Mar 2024